Comparing Injection Site Reactions of Aprepitant and Fosaprepitant in Gynecologic Cancer Chemotherapy.

Seira Nishibe-ToyosatoYosuke AndoYutaka ToriiRyoko IchikawaAkiko OwakiHironori MiyamuraEiji NishioHidezo MatsudaNaho Tsujii-FujiiAkane Shimato-IsobeKotone MukaijiKaori ItoTakahiro HayashiTakuma FujiiShigeki Yamada

Published in: In vivo (Athens, Greece) (2024)

Fos APR may increase the risk for ISR associated with TC±Bev therapy for gynecological cancer.

Keyphrases

papillary thyroid
squamous cell
lymph node metastasis
young adults
endometrial cancer
chemotherapy induced
rectal cancer